Abstract teal glass structures forming a shared framework, representing the move towards standardised HTA modelling.
Whitepaper icon
Publications

NICE’s approach to health economic modelling is evolving. In selected disease areas, the traditional reliance on bespoke, company-developed models is giving way to more standardised frameworks, with implications for how manufacturers prepare and defend their HTA submissions.

At ISPOR Europe 2026, Valid Insight presented research examining this transition, the changing role of manufacturers in model development, and the opportunities and limitations of generative artificial intelligence (GenAI).

Our poster, From Bespoke Models to Shared Infrastructure: NICE ECD18 and the Future of HTA Modelling (HTA386), presents a targeted narrative review of NICE appraisals and methodological developments from 2016 to October 2026, alongside emerging evidence on GenAI in health economics and outcomes research (HEOR).

Key findings

1. NICE is moving towards more standardised economic models

NICE’s ECD18 position statement introduces disease-specific reference case extensions that establish modelling requirements for selected indications. Its first extension, published in May 2026, covers overweight and obesity in adults, with metabolic dysfunction-associated steatohepatitis (MASH) planned to follow.

This represents a shift towards greater consistency in model design, although bespoke modelling remains the default outside the selected disease areas.

2. The focus of manufacturer input is changing

Where reference case extensions apply, manufacturers have less discretion over aspects of model structure and design. The emphasis increasingly shifts towards the quality of clinical evidence, robust indirect treatment comparisons (ITCs), and the justification of model inputs and assumptions.

The review highlights the importance of understanding which elements are prescribed by NICE and where manufacturers can still influence the assessment.

3. GenAI offers opportunities, but expert oversight remains essential

The research also examines published evidence on GenAI across evidence screening, data extraction, network meta-analysis, real-world evidence, and economic model development.

While some studies report performance approaching that of human reviewers for screening and extraction, evidence for more complex modelling tasks remains limited. Model development is particularly challenging, with inconsistent outputs and continuing requirements for expert validation.

Implications for HTA preparation

For manufacturers, NICE ECD18 may change where pre-submission effort delivers the greatest value.

Understanding the applicable modelling framework early, identifying which assumptions remain open to challenge, and investing in robust evidence generation will become increasingly important where standardised approaches apply.

GenAI may help improve efficiency in selected activities, but methodological judgement and quality assurance remain central to credible HTA submissions.

Download the full research poster to explore the evolution of NICE modeling approaches, the changing role of manufacturers and the evidence on GenAI capabilities across HEOR activities.

Publication details

Poster: HTA386
Conference: ISPOR Europe 2026, Vienna, Austria
Presentation date: 11 November 2026
Authors: Gareth Wynne-McHardy, Amanda Hansson Hedblom, Anna McCormick, and Gerdi Strydom
Organisation: Valid Insight, part of the Bioscript Group

Open economic assessment dossier with charts and text brought into focus through a transparent glass lens.
Whitepaper icon
Publications

NICE technology appraisals routinely raise methodological concerns about submitted clinical evidence and economic models. For manufacturers preparing an HTA submission, understanding which criticisms are widespread and which are associated with greater overall critique burden can help inform pre-submission evidence planning.

Valid Insight reviewed committee papers for 96 NICE technology appraisals published between 1 January 2025 and 7 May 2026. Using a structured protocol, the study recorded ten predefined critique domains and examined their associations with appraisal characteristics and final NICE recommendation outcomes.

Key findings

1. Six critique domains were almost universal

Six of the ten domains appeared in 84% to 100% of appraisals, with uncertainty critique raised in every case. Because these concerns offered limited differentiation between appraisals, they were excluded from a four-domain core issues score.

This distinction is important when evaluating the extent of methodological scrutiny: the presence of commonly raised concerns does not necessarily indicate an unusually problematic submission.

2. Indirect treatment comparisons were associated with greater critique burden

Appraisals using indirect treatment comparisons (ITCs) had higher core issues scores than those without them. The association remained statistically significant after adjustment for multiple testing, including in sensitivity analyses excluding cost comparisons and restricted to single technology appraisals.

Comparative efficacy critique was also associated with greater overall critique burden. Model structure critique showed a similar association in the unadjusted analysis, but this did not remain statistically significant after correction for multiple testing.

These findings highlight comparative efficacy estimation and model structure as areas warranting careful pre-submission scrutiny.

3. Critique burden was not significantly associated with NICE recommendation outcomes

Among the 92 appraisals with a final decision, the overall core issues score did not differ significantly between unrestricted recommendations and other outcomes. No individual core critique domain was independently significantly associated with an unrestricted recommendation.

The findings, therefore, do not support using the number of documented methodological critiques as a predictor of the final NICE recommendation.

Implications for HTA and market access

For pharmaceutical manufacturers, the research supports a focused approach to pre-submission preparation: reviewing NICE precedents for comparable technologies, obtaining clinical input on model structure and comparator selection, and ensuring ITC methods and assumptions are robust and defensible.

The analysis identifies associations rather than causal relationships. It was limited to one committee paper per appraisal and included only five appraisals that were not recommended, constraining the assessment of recommendation outcomes.

The findings provide a basis for prioritising methodological review, but do not establish that addressing particular critiques will improve reimbursement outcomes.

Download the full research poster

Publication details

Poster title: Prioritising Pre-Submission Investment: Associations Between Health Economic Model Characteristics and NICE TA Critique Burden and Recommendation Outcomes

Authors: Gareth Wynne-McHardy, Amanda Hansson Hedblom, Anna McCormick and Gerdi Strydom

Conference: ISPOR Europe 2026, Vienna, Austria

Poster number: HTA55

Presentation: Monday, 9 November 2026, Poster Session 1 (10:30–13:30 CET); author discussion 12:30–13:30 CET

Translucent multicoloured rare disease awareness ribbon with fragmented connections symbolising gaps in healthcare and policy
Whitepaper icon
Publications

European rare disease policy gaps: Bridging the gap between ambition and lived experience

Despite advances in European rare disease policy, research and specialist networks, significant gaps remain between policy ambitions and the support available to patients and caregivers.

Drawing on the lived experience of Erika Stariha, co-founder of SATB2 Europe and caregiver to a child with SATB2-associated syndrome, Valid Insight examined how effectively existing European policy initiatives respond to unmet needs throughout the rare disease care journey.

What the research found

The research identified nine unmet needs across the pre-diagnosis, diagnosis, and post-diagnosis stages, as well as cross-cutting challenges. These were assessed against 12 EU and UK policy initiatives and programs.

Six of the nine needs were partially addressed, while three remained largely unaddressed:

  • Psychological support during diagnostic uncertainty.
  • Structured handover to specialist networks and patient communities at diagnosis.
  • Sustainable funding for services is often provided by patient foundations.

The findings highlight the need to translate existing policy commitments, research infrastructure and specialist expertise into practical, coordinated and sustained support for families.

Download the research poster below to explore the full analysis, policy mapping and implications for a more effective European response to rare diseases.

A striking blue glass sculpture featuring the letter M, elegantly designed with a reflective surface.
Whitepaper icon
Publications
Preparing for the imapct of ESG
Whitepaper icon
Publications
A person holds a camera lens, with a serene lake visible in the background.
Whitepaper icon
Publications
Think Tank
Whitepaper icon
Publications
Sustainability in Pharma
Whitepaper icon
Publications

    To download this document, please provide your details

    By submitting your details, you adhere to our privacy policy

    Thank you, your download has started

    If you brochure doesn't download, click here